Your search for Janus kinase inhibitor returned 174 results

Ojjaara, a JAK inhibitor, is supplied as 100mg, 150mg, and 200mg tablets in 30 -count bottles.

The application is supported by data from two phase 3 trials: an induction study, INSPIRE and a maintenance study, COMMAND.

Study shows safety and tolerability of JAK inhibitors acceptable.

No new safety signals were observed in this patient population.

Litfulo is supplied as a 50mg capsule and is expected to be available in the coming weeks.

Overview On March 11, 2020, the World Health Organization (WHO) declared a global pandemic of a novel respiratory coronavirus, now known as SARS-CoV-2.1 Rapid spread of the original virus and its multiple variants led to more than 1 million deaths in the United States and nearly 7 million deaths worldwide by the time the WHO…

The approval was based on studies that included adults with moderately to severely active Crohn disease who had an inadequate response to or were intolerant of biologic therapy.

Significantly greater ACR20 response rates seen at week 16 for 30 and 60mg QD vs placebo; response maintained or improved at 52 weeks.

The letter states that the application cannot be approved in its present form.

Results showed that 20.3% of patients treated with risankizumab achieved clinical remission at week 12 compared with 6.2% of patients who received placebo.